Bezlotoxumab

ApprovedTerminated

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Inflammatory Bowel Diseases

Conditions

Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease, C. Diff. Infections

Trial Timeline

Oct 14, 2021 → May 31, 2024

NCT ID

NCT04626947

About Bezlotoxumab

Bezlotoxumab is a approved stage product being developed by Merck for Inflammatory Bowel Diseases. The current trial status is terminated. This product is registered under clinical trial identifier NCT04626947. Target conditions include Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease.

What happened to similar drugs?

9 of 20 similar drugs in Inflammatory Bowel Diseases were approved

Approved (9) Terminated (2) Active (11)

✅Infliximab + Infliximab + InfliximabCelltrionApproved

✅fidaxomicinAstellas PharmaApproved

✅RisankizumabAbbVieApproved

✅Human Papillomavirus VaccineMerckApproved

✅Celecoxib + Ibuprofen plus OmeprazolePfizerApproved

✅Alemtuzumab infusionSanofiApproved

✅IgPro10CSLApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04626947	Approved	Terminated	Oct 14, 2021	May 31, 2024	Inflammatory Bowel Diseases
NCT03937999	Approved	Terminated	Aug 30, 2019	May 15, 2022	Clostridium Difficile
NCT03756454	Approved	Terminated	Aug 19, 2019	May 23, 2022	Clostridia Difficile Colitis

Competing Products

20 competing products in Inflammatory Bowel Diseases

See all competitors

Product	Company	Stage	Hype Score
Infliximab + Infliximab + Infliximab	Celltrion	Approved	50
CT-P13	Celltrion	Phase 3	36
Subcutaneous infliximab CT-P13 Remsima®SC	Celltrion	Pre-clinical	22
Infliximab subcutaneous + Immunosuppressive Agents	Celltrion	Phase 3	47
fidaxomicin	Astellas Pharma	Approved	43
Eribulin + Adriamycin + Cyclophosphamide	Eisai	Phase 2	39
E6007 + E6007 + E6007 + E6007 + E6007 + E6007	Eisai	Phase 1	29
Placebo + MORF-057	Eli Lilly	Phase 2	42
Baricitinib + Baricitinib	Eli Lilly	Phase 2	35
LY3114062 SC + Placebo + LY3114062 IV	Eli Lilly	Phase 1	29
MORF-057 + Placebo	Eli Lilly	Phase 2	39
MORF-057	Eli Lilly	Phase 2	35
LY3009104	Eli Lilly	Phase 1	29
HRF2105 patch + Loxoprofen patch + placebo	Jiangsu Hengrui Medicine	Phase 2	31
Risankizumab	AbbVie	Approved	43
GC012F Injection infusion	AstraZeneca	Phase 1	36
AZD6793 + Placebo	AstraZeneca	Phase 1	29
Human Papillomavirus Vaccine	Merck	Approved	43
Pembrolizumab	Merck	Phase 2	31
Gardasil vaccine	Merck	Pre-clinical	26